Skip to main content
logo
LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
4.290
+0.790 (22.57%)
At close: Nov 9, 2026, 4:00 PM EST
4.200
-0.090 (-2.10%)
Pre-market: Nov 10, 2026, 7:32 AM EST

LENZ Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
12.3619.09--15-
Revenue Growth
-29.38%-----
Cost of Revenue
2.230.42----
Gross Profit
10.1318.67--15-
Selling, General & Admin
159.8291.1428.8112.934.362.47
Research & Development
-18.6729.859.521.134.22
Operating Expenses
159.82109.8158.6172.4325.486.69
Operating Income
-149.69-91.14-58.61-72.43-10.48-6.69
Interest & Investment Income
9.899.768.552.190-
Other Non Operating Income (Expenses)
-0.26-0.240.290.090.02-0.87
Pretax Income
-140.27-81.63-49.77-70.15-10.46-7.56
Income Tax Expense
0.010.50-0.180.35-
Net Income
-140.27-82.13-49.77-69.97-10.81-7.56
Net Income to Common
-140.27-82.13-49.77-69.97-10.81-7.56
Net Income Growth
------
Shares Outstanding (Basic)
312921299
Shares Outstanding (Diluted)
312921299
Shares Change
12.13%35.39%986.27%-79.28%1.05%-
EPS (Basic)
-4.48-2.85-2.34-35.71-1.14-0.81
EPS (Diluted)
-4.48-2.85-2.34-35.71-1.14-0.81
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-127.7-70-59.86-60.41-4.13-5.4
Free Cash Flow Per Share
-4.08-2.43-2.81-30.84-0.44-0.58
Gross Margin
81.97%97.81%--100.00%-
Operating Margin
-1211.17%-477.46%---69.89%-
Profit Margin
-1134.97%-430.25%---72.07%-
Free Cash Flow Margin
-1033.28%-366.71%---27.52%-
EBITDA
-149.25-90.85-58.55-72.41-10.48-6.69
EBITDA Margin
-----69.83%-
D&A For EBITDA
0.440.290.060.020.010
EBIT
-149.69-91.14-58.61-72.43-10.48-6.69
EBIT Margin
-----69.89%-
Revenue as Reported
12.3619.09--15-
Advertising Expenses
-8----
SEC Filings: 10-K · 10-Q